Home
 /
Papers
 /
Biophysics
 /
Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia
Preprint
Open access
Top 1% · Validated by QED

Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia

Gandhar K. Datar, Elmira Khabusheva, Archish Anand +22 more
May 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.05.23.655671
99
%
QED Score
QED Impressions

By demonstrating that NPM1c, NUP98, and KMT2A oncofusions all drive leukemia through biophysically identical phase-separated condensates, this work unifies disparate AML subtypes under a single mechanism and reframes condensate dissolution as a principled therapeutic strategy.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

NPM1c mutations drive acute myeloid leukemia through formation of nuclear phase-separated condensates termed coordinating bodies (C-bodies) that recruit NUP98, KMT2A, MENIN, and XPO1 to activate HOXA/MEIS1 gene expression, with C-body formation being both necessary and sufficient for maintaining the leukemic state, and nucleoporin and KMT2A fusion proteins from other leukemia subtypes forming biophysically indistinguishable C-bodies, establishing these condensates as a unifying therapeutic target across multiple leukemia types.

See full analysis
Main Claim 1 –

NPM1c Forms Nuclear Condensates Distinct from Nucleoli

Supporting evidence

  • NPM1c Condensates Form During Telophase via Segregation from NPM1wt
Main Claim 2 –

NPM1c Condensates Recruit Leukemia-Relevant Chromatin Regulators

Main Claim 3 –

NPM1c Is Necessary and Sufficient for C-Body Recruitment

Supporting evidence

  • C-Bodies Arise from Concentration-Dependent Heterotypic Phase Separation
Main Claim 4 –

C-Body Composition Changes Alter HOXA/MEIS1 and Promote Differentiation

Abstract

During cancer development, mutations promote gene expression changes that cause transformation. Leukemia is frequently associated with aberrant HOXA expression driven by translocations in nucleoporin genes or KMT2A, and mutations in NPM1. How disparate mutations converge on this regulatory pathway is not understood. Here we demonstrate that mutant NPM1 (NPM1c) forms nuclear condensates in multiple human cell lines, mouse models, and primary patient samples. We show NPM1c phase separation is necessary and sufficient to coordinate the recruitment of NUP98 and KMT2A to condensates. Through extensive mutagenesis and pharmacological destabilization of phase separation, we find that NPM1c condensates are necessary for regulating gene expression, promoting in vivo expansion, and maintaining the undifferentiated leukemic state. Finally, we show that nucleoporin and KMT2A fusion proteins form condensates that are biophysically indistinguishable from NPM1c condensates. Together, these data define a new condensate underlying leukemias that we term coordinating bodies (C-bodies), and propose C-bodies as a therapeutic vulnerability.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?